Global InformationBiovest information
 | This article reads like a press release or a news article and may be largely based on routine coverage. (August 2017) |
| Company type | Public |
|---|---|
| Industry | Biomedicine |
| Headquarters | Minneapolis, MN , United States |
Key people | Dr. Rebecca Thompson (Chief Executive Officer) |
| Products | BiovaxID (dasiprotimut-T) |
| Services | Autologus active immunotherapy (cancer vaccines) |
Number of employees | 50 |
| Website | www.cellculturecompany.com |
Biovest International, Inc (OTCQB: BVTI) was a Minneapolis-based biotechnology company. Their active immunotherapy, BiovaxID, is a cancer vaccine whose first indication was intended to be consolidation/adjuvant therapy of follicular Non-Hodgkin's Lymphoma. Biovest filed to reorganize under chapter 11 bankruptcy in 2014,[1] BiovaxID was refused European marketing authorization in 2015,[2] and Biovest's stock listing was revoked in 2017.[3]
- ^ "Biovest International, Inc. Files for Bankruptcy" (Press release). BioVest. March 8, 2013. Retrieved July 8, 2023 – via BioSpace.
- ^ "European Medicine Agency Recommends Refusal of the Marketing Authorisation for Dasiprotimut-T". European Society for Medical Oncology. April 28, 2015. Retrieved July 8, 2023.
- ^ "Form REVOKED Biovest International Inc. REVOKED - Commission order revoking Exchange Act registration [Section 12(j)]". SEC.report. October 4, 2017. Archived from the original on August 5, 2021. Retrieved July 8, 2023.